Research progress on gene mutation of jak2.
- Author:
Li LIU
1
;
Wei LI
;
Nian LIU
;
Lei PANG
;
Si-Xia FENG
;
Ling-Ling ZHAO
Author Information
1. Cancer Center, The First Hospital, Jilin University, Changchun 130021, Jilin Province, China.
- Publication Type:Journal Article
- MeSH:
Chronic Disease;
Humans;
Janus Kinase 2;
genetics;
Mutation;
Myelodysplastic-Myeloproliferative Diseases;
genetics
- From:
Journal of Experimental Hematology
2009;17(6):1629-1632
- CountryChina
- Language:Chinese
-
Abstract:
Chronic myeloproliferative disease (CMPD) is a group of malignant blood disorders including polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic myeloid leukemia, and so on. CMPD is characterized by proliferation of one or several lineages in hematopoietic system. The pathogenesis of CMPD is not clear except chronic myeloid leukemia associated with the bcr/abl fusion gene. In recent years, more studies demonstrated that CMPD have a higher mutation rate of gene jak2. In this review, the association of jak2 gene mutation with clinical diagnosis, clinical feature and molecular target therapy in CMPD and other hematological disease were summarized.
